Apoptotic and antiproliferative effects of gemcitabine and gemcitabine plus Ara-C on blast cells from patients with blast crisis chronic myeloproliferative disorders

Haematologica

Volumn 82, Issue 1, 1997, Pages 11-15

  Santini, Valeria ^a   Bernabei, Pietro Antonio ^a   Gozzini, Antonella ^a   Scappini, Barbara ^a   Zoccolante, Antonella ^a   D'Ippolito, Gianluca ^a   Figuccia, Marina ^a   Ferrini, Pierluici Rossi ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Apoptosis; Ara C; Chronic myeloproliferative disorders blast crisis; Gemcitabine

Indexed keywords

BCR ABL PROTEIN; CYTARABINE; DNA FRAGMENT; GEMCITABINE;

ARTICLE; BLAST CELL CRISIS; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; CELL STRAIN HL 60; CHRONIC MYELOID LEUKEMIA; COLONY FORMATION; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MYELOPROLIFERATIVE DISORDER;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BLAST CRISIS; CELL CYCLE; CYTARABINE; DEOXYCYTIDINE; DNA, NEOPLASM; DRUG SYNERGISM; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MYELOFIBROSIS; THROMBOCYTHEMIA, HEMORRHAGIC; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 0031451376     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Clavio M, Carrara P, Miglino M, et al. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. Haematologica 1996; 81:513-20.
2. Visani G, Tosi P, Zinzani PL, et al. FLAG (fludarabine + cytosine arabinoside+G-CSF) induces complete remission in acute phase chronic myeloid leukemia: a case report. Br J Haematol 1994; 86:394-6.
3. Gandhy V, Plunkett W. Modulatory activity of 2′,2′-difluoro-2′-deoxycytidine on the phosphorylation and cytotoxicity of arabinosylnucleosides. Cancer Res 1990; 50:3675-80.
4. Hertel LW, Border JB, Kroin JS, et al. Evaluation of antitumor activity of Gemcitabine (2′-2′-difluoro-2′-deoxycytidine). Cancer Res 1990; 50:4417-22.
5. Zinzani PL, Buzzi M, Farabegoli P, et al. Apoptosis induction with fludarabine on freshly isolated chronic myelogenous leukemia cells. Haematologica 1994; 79:127-31.
6. Santini V, D'Ippolito G, Bernabei PA, Zoccolante A, Ermini A, Rossi Ferrini P. Effects of fludarabine and gemcitabine on HL 60 cells: direct comparison of cytotoxicity and cellular Ara-C uptake enhancement. Leuk Res 1996; 20:36-45.
7. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myetogenous leukemia: a concise update. Blood 1993; 82:691-703.
8. Mc Gahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG. Bcr/Abl maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994; 83:1179-87.
9. Santucci MA, Saglio G, Tura S. Pathogenesis and progression of chronic myeloid leukemia. Haematologica 1996; 81:63-70.
10. Santini V, Zoccolante A, Bosi A, et al. Detection of bcr/abl transcripts by RT-PCR and their colorimetric evaluation in chronic myeloid leukemia patients receiving allogeneic bone marrow transplantation. Haematologica 1996; 81:201-7.
11. Peters GJ, Ruiz van Haperen VWT, Noordhuis P, Veerman G, Vermorken JB. Clinical pharmacology of Gemcitabine (2′-2′-difluorodeoxycytidine, dFdC) in relation to accumulation of its active metabolite dF-dCTP in normal and tumor cells. Eur J Cancer 1991; 27suppl:S195.
12. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanism of action and self-potentiation. Semin Oncol 1995; 22(suppl 11):3-10.
13. Braakhuis BJM, Ruiz van Haperen VWT, Boven E, Veerman G, Peters GJ. Schedule-dependent antitumor effect of Gemcitabine in in vivo model systems. Semin Oncol 1995; 22(suppl 11):42-6.
14. Tonato M. Gemcitabine safety overview. Proc. Satellite Symposium ECCO 1993:7.
15. Peters GJ, Plunkett W. Gemcitabine: status of preclinical studies and perspectives for future clinical applications of this novel nucleotide analog. Semin Oncol 1995; 2(suppl 11):1-2.
16. Bergamaschi G, Rosti V, Danova M, Lucotti C, Cazzola M. Apoptosis: biological and clinical aspects. Haematologica 1994; 79:86-93.
17. Enari M, Hug H, Nagata S. Involvement of an ICE-like protease in Fas mediated apoptosis. Nature 1995; 375:78-81.
18. Sachs L, Lotem J. Control of programmed cell death in normal and leukemic cells: new implications for therapy. Blood 1993; 82:15-21.
19. Huang P, Plunkett W. Induction of apoptosis by Gemcitabine. Semin Oncol 1995; 22(suppl 11): 19-26.